These innovative agents represent a significant advancement in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://monicawcqc153397.tribunablog.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-53481291